Human osteosarcoma cells respond to sorafenib chemotherapy by downregulation of the tumor progression factors S100A4, CXCR4 and the oncogene FOS

Ingrid Walter(University of Veterinary Medicine Vienna), Ralf Steinborn(University of Vienna)
Oncology Reports
December 30, 2013
Cited by 14


Related Papers